Important Information for Investors: Securities Fraud Allegations against Zynex, Inc.
New York, March 28, 2025 – Levi & Korsinsky, LLP announces that a class action securities lawsuit has been commenced in the United States District Court for the Southern District of New York on behalf of investors who purchased Zynex, Inc. (“Zynex” or the “Company”) (NASDAQ: ZYXI) securities between March 13, 2023, and March 11, 2025. The lawsuit seeks to recover damages for Zynex investors who were adversely affected by alleged securities fraud.
Class Definition
The class definition includes all persons or entities who purchased or otherwise acquired Zynex securities between March 13, 2023, and March 11, 2025, inclusive (the “Class Period”).
Allegations
The complaint alleges that Zynex and certain of its top executives made false and misleading statements to the market and investors regarding the Company’s business, operational, and financial metrics. Specifically, the complaint alleges that the defendants failed to disclose:
- That Zynex was experiencing significant declines in sales, particularly in its Neurostim Division;
- That the Company’s financial statements contained material misstatements and omissions;
- That the Company’s revenue growth was due in large part to one-time events and was not sustainable;
- That the Company was experiencing significant customer concentration risk;
- That the Company’s financial condition was weaker than represented;
Impact on Individual Investors
If you purchased Zynex securities during the Class Period, you may be entitled to recover your losses, including damages for any financial losses, as well as an award of attorneys’ fees and costs. To determine whether you may be entitled to recover damages, contact Levi & Korsinsky, LLP as soon as possible.
Impact on the World
The securities fraud allegations against Zynex could have significant repercussions for the healthcare technology industry as a whole. The allegations of misrepresentation and financial mismanagement could lead to increased scrutiny and regulation of publicly-traded healthcare technology companies. Additionally, investors may become more cautious when considering investments in this sector, potentially leading to a decrease in investment activity and a slowdown in innovation.
Conclusion
The securities fraud allegations against Zynex, Inc. are a serious matter that could have significant implications for investors and the healthcare technology industry as a whole. If you purchased Zynex securities during the Class Period, it is important that you understand your rights and potential remedies. Levi & Korsinsky, LLP is committed to helping investors recover their losses and holding companies accountable for their actions. For more information, please contact Levi & Korsinsky, LLP as soon as possible.
Levi & Korsinsky, LLP
30 Broad Street, 14th Floor
New York, NY 10004
Email: info@levikorsinsky.com
Phone: 212-363-7500
Toll Free: 877-363-5972
Fax: 212-363-7171
Source: Levi & Korsinsky, LLP
ATTORNEY ADVERTISING. THE FOLLOWING STATMENT IS BEING MADE PURSUANT TO THE PRIVATE SECURITIES LITIGATION REFORM ACT OF 1995.
ADVERTISEMENT. This press release may be considered an advertisement or solicitation under the Private Securities Litigation Reform Act of 1995. The information contained in this press release is not intended to constitute legal or professional advice. No attorney-client relationship is formed with any person or entity who contacts this office or who visits this website. Please review our full disclaimer at https://www.levikorsinsky.com/disclaimer/.
